Actively Recruiting
Evaluating Safety and Effectiveness of HGI-001 Injection Using Modified Stem Cells in Adults With Severe Transfusion-Dependent Beta-Thalassemia Aged 18 to 35
Led by Shenzhen Hemogen · Updated on 2024-11-29
3
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This trial investigates the safety and effectiveness of using beta-globin restored autologous hematopoietic stem cells in patients with transfusion-dependent beta-thalassemia major. The study focuses on patients aged 18 to 35 who require frequent blood transfusions due to this genetic blood disorder. Researchers aim to evaluate how this gene-modified stem cell therapy impacts disease outcomes and patient health over time. Participants will have their own hematopoietic stem cells collected and modified with the LentiHBBT87Q system to restore beta-globin production. Following a conditioning regimen, these modified cells will be reinfused back into the patient. The study is open-label and includes a two-year follow-up period to monitor how the treatment works and any effects it may have. Throughout the study, participants will undergo various assessments including monitoring for adverse events, survival rates, and changes in transfusion needs. Researchers will also evaluate hematology, bone marrow health, viral integration, iron levels in the heart and liver, and other markers related to treatment response. Participants are expected to attend regular visits over two years for these evaluations and to support adherence to the treatment and follow-up schedule.
CONDITIONS
Brief Title
the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia
Research Team
H
Haigang Sun
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here